Bladder cancer, in contrast, demonstrates increased TLS activity, particularly in high-grade disease, with high TLS density associated with superior responses to Bacillus Calmette-Guérin (BCG) therapy and anti-PD-L1 treatment. The gene discussed is CD274; the disease is urinary bladder cancer.